After every sales meeting, there is a window when the physician or administrator reflects on the conversation before the next vendor arrives. What they have in their hands during that window matters enormously.
A one-page leave-behind is your device’s commercial argument at its most essential: what it is, what problem it solves, what the evidence shows, and what the next step looks like. It is not a brochure. It’s not a mini deck. It’s one page, designed to be read quickly, referenced later, and shared internally with other stakeholders the rep hasn’t met yet.
The one-pager serves a secondary purpose that most reps underestimate. When a clinical champion wants to advocate for your product internally, they need something to circulate. They’re not going to forward a 40-slide deck. They will forward a clean, clear one-pager that makes the case for them. Giving champions that tool is part of how deals move forward without the rep present.
The one-pager should be stakeholder-flexible where possible. Language that a surgeon can share with a materials manager, and that a materials manager can hand to a supply chain director, compresses the internal selling cycle significantly.
4. An Economic Value Tool That Speaks the CFO's Language
Hospital purchasing environments have become structurally more financial in their decision-making. Value-based care models, tighter margins, and centralized procurement have all shifted the weight of a purchase decision toward administrators and financial stakeholders who were historically peripheral to device selection.
An economic value tool is typically a simple model that helps a financial buyer understand the cost impact of adopting your device. The most common format is a budget impact model: what does current standard of care cost the institution, and how does your device change that calculation? That can mean reduced procedure time, fewer complications, shorter length of stay, lower readmission rates, or some combination of those factors. The model should be transparent in its assumptions, conservative in its estimates, and simple enough that a hospital CFO’s staff can audit it without your rep in the room.
According to research published by Intuition Labs analyzing medtech sales force performance, hospital procurement teams increasingly “require health economic evidence and ROI cases” rather than clinical feature-based selling alone. That shift has moved economic value tools from nice-to-have to table stakes in hospital sales environments.
This is also the asset that most small and mid-size medtech companies build last and should be building first. By the time a rep reaches a value analysis committee or a CFO, the absence of an economic model is not just a gap in the sales toolkit. It reads as organizational unpreparedness.
5. A Battlecard That Prepares Reps for the Competitive Conversation
No rep should walk into a hospital without knowing exactly how their device compares to the two or three alternatives that the institution is already using or currently evaluating. The battlecard is the internal tool that makes that preparation possible.
A medtech battlecard is not a marketing document. It’s not shared with customers. It’s a rep-facing resource that maps competitive products side-by-side against your device on the dimensions that actually matter in a hospital purchase decision: clinical outcomes, procedure time, cost per use, contract flexibility, support model, and reimbursement positioning. It also captures the objections reps are most likely to hear from each stakeholder type, and it provides guidance on how to respond credibly without overclaiming.
The battlecard is one of the most frequently used assets a rep has, and one of the most frequently neglected in terms of maintenance. Competitive dynamics shift. Competitors get new clearances, update pricing, lose or win accounts. A battlecard that was accurate eighteen months ago may actively mislead a rep today. Building a process to update competitive intelligence and refresh the battlecard on a regular cadence is as important as building it in the first place.
Used well, the battlecard also surfaces where your device has genuine disadvantages. Acknowledging those limitations honestly in a sales conversation, when appropriate, builds the kind of credibility that closes deals that pure advocacy cannot.
The Asset Gap Most Companies Don't See Until It's Too Late
These five assets don’t function independently. A rep who has the sales deck but not the economic value tool will stall at the CFO. A rep who has the one-pager but not the clinical evidence summary will lose credibility in a peer-to-peer conversation. A rep who has all four but no battlecard will be caught flat-footed the moment a competitor’s name comes up, which it always does.
The more important point is that building these assets reactively, after launch, in response to what reps ask for in the field, is one of the most common and most expensive commercial mistakes in medtech. The Matchstick Group, in their analysis of medical device launch readiness, notes that most companies “build their sales enablement materials reactively, responding to what reps ask for after launch rather than anticipating what they need before it.” By the time the gaps are filled, the launch window has narrowed and competitive positioning has been set by whoever arrived better prepared.
The companies that build these assets before reps hit the field compress the sales cycle, increase first-call credibility, and give their champions the tools to advocate internally. The ones that don’t spend the next twelve months patching a commercial infrastructure that should have been in place at the start.
Frequently Asked Question
Sunny Singh – Fractional CMO
If your sales team is heading into the field without these assets, or if the ones you have aren't converting, that's worth a conversation. I work with medtech companies as a fractional CMO to build the commercial infrastructure that supports scalable growth.